Question 1

What does semaglutide do?

Accepted Answer

Two outcomes have been measured in thousands of people, and everything beyond them is considerably thinner. The first is body weight. In the 2021 obesity trial the mean change in body weight from baseline to week 68 was -14.9% in the semaglutide group as compared with -2.4% with placebo, in adults who also received a lifestyle intervention. The second is blood sugar: in the 2017 diabetes trial, at week 30, HbA1c significantly decreased by 1·45% with 0·5 mg semaglutide. HbA1c is a blood test reflecting the average blood sugar concentration over roughly three months. Everything further down this page is either an outcome measured inside one of those trials, such as body composition, or a question that none of the studies covered here has yet asked at all. The distinction between those two categories is the organising principle of everything below.

Question 2

How much weight did people lose on semaglutide?

Accepted Answer

Between roughly 10% and 15% of starting weight in the randomised trials, and the figure moves with how you count. The largest single-trial figure in adults is -14.9% at week 68 against -2.4% with placebo. Pooling brings it down. A 2024 meta-analysis identified six RCTs comprising 3962 overweight or obese individuals and put the mean difference at -11.80% of body weight against placebo, while a 2022 meta-analysis of 4 randomized controlled trials having a total of 3,613 individuals with obesity without diabetes recorded a mean difference for weight reduction of -11.85%, favoring semaglutide. Read the gap between the single trial and the pooled figures, because it is not an error. A pooled estimate averages across populations, durations and completion rates, which is why it sits lower than the strongest single result and is the more conservative of the two numbers.

Question 3

What mechanism is behind semaglutide's weight loss?

Accepted Answer

By acting on a receptor that sits in several organs at once. A 2019 review notes that GLP-1RAs mediate their effects via this receptor, which is expressed in the pancreas, gastrointestinal tract, heart, lungs, kidneys, and brain. GLP-1RA stands for glucagon-like peptide-1 receptor agonist, the family semaglutide belongs to. The same review attributes the weight effect to intake rather than to expenditure, describing significant weight loss, through an effect to reduce energy intake. A 2021 review of the class is more specific, listing deceleration of gastric emptying preventing large post-meal glycemic increments, and a reduction in calorie intake and body weight. So the mechanism on the record is about eating less, not about burning more. That distinction matters, because the two would predict different things once a weekly injection stops, and only one of them has been measured.

Question 4

How long does it take for semaglutide to work?

Accepted Answer

No study among the research behind this page has published a week-by-week answer, and that gap is considerably wider than it first appears, because the randomised readouts land at 30, 44, 68 and 104 weeks and the shortest of them already represents more than half a year. Three figures from three separate trials give the shape of the thing without giving the curve. At 44 weeks, estimated mean percentage change in bodyweight from baseline to week 44 was -12·1% with semaglutide 2·4 mg versus -3·6% with placebo. At 68 weeks the figure was -14.9% against -2.4%, and at 104 weeks it was -15.2% in the semaglutide group versus -2.6% with placebo. Lining those up as a time course is a comparison nobody made, because they come from three separate trials in three different populations, which makes the sequence suggestive rather than measured, and no trial among the research behind this page reports a figure at four weeks or at twelve.

Question 5

How long does it take to suppress appetite?

Accepted Answer

No trial among the research behind this page has measured the time to an appetite change in people given semaglutide. What exists is the mechanism, stated as an endpoint rather than a stopwatch: a 2019 review describes significant weight loss, through an effect to reduce energy intake. A 2021 review of the class puts the same thing physiologically, listing deceleration of gastric emptying preventing large post-meal glycemic increments. Gastric emptying is how quickly the stomach passes food on, and slowing it is the mechanism most often invoked for feeling full sooner. Read what that does and does not establish, because eating less is the route the weight figures are attributed to, which means it has to begin before the weight moves. When it begins, how strongly it is felt, and whether it fades are different questions, and no trial among the research behind this page has asked them.

Question 6

What did semaglutide do for type 2 diabetes?

Accepted Answer

Lowered HbA1c in every trial that measured it. In the 2017 monotherapy trial, 387 patients who had managed with diet and exercise alone were randomised, and at week 30, HbA1c significantly decreased by 1·45% with 0·5 mg semaglutide. A 2021 head-to-head trial measured the same thing against tirzepatide in 1879 patients over 40 weeks, where the estimated mean change from baseline in the glycated hemoglobin level was -1.86 percentage points with semaglutide at 1 mg. Glycated hemoglobin is the full name for HbA1c. Weight came with it. In adults who had both overweight or obesity and type 2 diabetes, estimated change in mean bodyweight from baseline to week 68 was -9·6% with semaglutide 2·4 mg vs -3·4% with placebo, which is a smaller figure than the same weekly amount produced in people without diabetes.

Question 7

Do semaglutide tablets work as well as the injection?

Accepted Answer

Close, on the figures published so far. A 2021 review records that a daily oral preparation of semaglutide, which has demonstrated clinical effectiveness close to the once-weekly subcutaneous preparation, was recently approved. For weight the tablet has a trial of its own. In 2025, the estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group, among 205 participants assigned to the tablet and 102 to placebo. That -13.6% sits beside the -14.9% from the injected trial, and the temptation is to call them equivalent. They were measured in separate trials, at different weeks, in differently sized groups, and nothing among the research behind this page compares the two routes head to head. Close is what the record supports, and equal is not the same claim.

Question 8

Is the weight lost fat or muscle?

Accepted Answer

Both, and the split is among the better-measured things here. A 2024 systematic review of six studies with 1,541 overweight or obese adults found that significant weight reductions were observed primarily due to fat mass loss. It also recorded that while the lean mass remained stable in some cases, notable reductions ranging from almost 0% to 40% of total weight reduction were observed in others. A 2025 network meta-analysis of twenty-two randomized controlled trials (2258 participants) is blunter. In those participants GLP-1RAs significantly reduced total body weight, fat mass, and lean mass, with lean mass loss comprising approximately 25 % of the total weight loss. A 2024 review in Diabetes Care puts a size on it in patients, reporting that these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging.

Question 9

What happened after two years?

Accepted Answer

The weight stayed off, in the one trial that ran that long. 304 participants were randomly assigned to semaglutide 2.4 mg or placebo, and more participants in the semaglutide group than in the placebo group achieved weight loss ≥5% from baseline at week 104 (77.1% versus 34.4%). A proportion is a different kind of fact from a mean, and here it is the more useful one, because a group average can be produced by a handful of very large responses whereas three quarters of a group crossing a five per cent threshold cannot be. One trial of 304 people is nevertheless still one trial. It ran with behavioral support throughout, it was not constructed to follow anybody after the injections stopped, and 104 weeks is as far as the published record reaches. Two years of maintained loss and indefinite maintenance are different questions.

Question 10

Did semaglutide work in adolescents?

Accepted Answer

In one trial, and with a different measure. A 2022 trial enrolled adolescents with obesity, and the mean change in BMI from baseline to week 68 was -16.1% with semaglutide and 0.6% with placebo. BMI is weight scaled to height, which is how body size is tracked in a population that is still growing. A total of 201 participants underwent randomization, and 180 (90%) completed treatment, which is a notably high completion rate for an investigation of that length. One trial in 201 adolescents is where the published record on this age group begins and ends. It reports a BMI change across 68 weeks, rather than what becomes of a fourteen-year-old over the following decade, and those are different questions entirely.

Question 11

Did it work outside the original trial populations?

Accepted Answer

One trial went looking. A 2024 trial recruited participants from 23 hospitals and trial centres in China, Hong Kong, Brazil, and South Korea, and randomised 375 of them to semaglutide 2·4 mg or placebo for 44 weeks. Routine care is the harder test, and it points the other way. A 2025 review reports that the observed weight reduction in clinical practice overall tends to be lower than in randomized controlled trials; however, outcomes approach those seen in trials when focusing on highly adherent patients. That second clause carries the whole finding, because the distance between trial results and practice is described there as a difference in who keeps taking it, rather than as a failure of the compound, and those are separate claims that get run together constantly.

Question 12

What did semaglutide do for the heart?

Accepted Answer

Less has been published than the attention would suggest. A 2019 review states that both liraglutide and semaglutide also positively affect cardiovascular (CV) outcomes in individuals with T2D, although the precise mechanism is still being explored. T2D is type 2 diabetes. The large dedicated trial is on the record as a design rather than as a result. Its primary outcome is time from randomization to first occurrence of a major adverse CV event (MACE; a composite of CV death, nonfatal myocardial infarction or nonfatal stroke), and 9650 participants were enrolled. So what exists is a class-level statement from a review and a trial built to test it in 9650 people. A protocol paper reports what will be measured rather than what was found, and the distance between those two is the whole of what can honestly be said here.

Question 13

What happens when people stop?

Accepted Answer

Nobody has published the answer, and it is the most consequential gap on this page. A 2025 review lists studies of the effects of stopping GLP-1RA treatment among the work still needed, which is an unusual admission for a compound trialled this heavily. What is documented is how often people stop. The same review reports high discontinuation rates of GLP-1RAs (20%-50%) within the first year, drawn from routine care records rather than from trials. Hold those two facts together, because separately each of them misleads. Somewhere between a fifth and a half of patients stop inside a year, and what happens to them afterwards has not been measured in any published trial. Every weight figure on this page describes people who were still taking it at the readout, which is a considerably narrower group than everyone who started.

Question 14

What is semaglutide being tested for now?

Accepted Answer

Four registered studies point outside weight and blood sugar. One is a phase 1 and 2 study of Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease, listed as RECRUITING. Another covers Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy, in 15 people. Nephropathy means kidney damage. A completed phase 2 study paired it with another compound, as a Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity. A completed phase 3 entry is listed simply as the Latino Semaglutide Study. None of those has reported yet. A registration is a plan rather than a result. For conditions outside that short list, including rheumatoid arthritis, there is no registered trial in these sources and no published measurement either.

Question 15

What brand name is semaglutide sold under?

Accepted Answer

Wegovy, for weight management. A 2022 review records that the trial results led to Food and Drug Administration approval of Wegovy (semaglutide) for weight loss. A 2025 FDA enforcement record lists Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton. The names that appear most often in the literature are not brands at all. SUSTAIN, PIONEER and STEP are research programmes. The same review spells them out as SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes), PIONEER (Peptide Innovation for Early Diabetes Treatment), and STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programs. That distinction is worth carrying. A brand names an approved presentation. A programme name identifies the trials behind it, and every outcome figure on this page comes from the second rather than the first.

Semaglutide: what the research measured